LHI.US Aims to Raise $600M in US IPO

LHI.US, a company based in China Hong Kong specializing in homeopathic products, has filed for an initial public offering (IPO) in the United States, aiming to raise up to $600 million. The company plans to issue 1.3 million shares at a price range of $4 to $6 per share, which, at the midpoint of the range, would value the company at approximately $56 million.

The company's core business revolves around the sale of health care products, including homeopathic remedies, which accounted for 9% of its 2024 fiscal year revenue, homeopathic synergistic therapy products at 80%, and flower essence therapy products at 4%. These products are primarily sourced from manufacturers and distributed under the company's own brand, "LIVING." Additionally, the company offers personal care products, such as mouthwash, toothpaste, and shampoo, which make up 2% of its revenue, and water filter products, which account for 4% and are developed in-house and manufactured by third-party suppliers.

LHI.US was established in 1994 and generated $800 million in revenue for the 12 months ending September 30, 2024. The company plans to list on the Nasdaq under the ticker symbol LHI. LHI.US confidentially submitted its IPO application on November 1, 2024, with Tiger Brokers serving as the sole bookrunner. The specific pricing terms have not yet been disclosed.

The decision to go public is part of LHI.US's broader strategy to expand its market presence and secure additional funding for research and development. The funds raised from the IPO will support the company's growth initiatives, including the development of new products and the expansion of its distribution network. This move positions LHI.US to capitalize on the growing demand for natural and alternative healthcare solutions.

The IPO filing with the U.S. Securities and Exchange Commission (SEC) is a significant step for LHI.US as it seeks to leverage U.S. capital markets to fuel its growth. By going public, LHI.US aims to attract a broader investor base and increase its visibility in the global market. The success of the IPO will depend on market conditions, investor sentiment, and the company's ability to demonstrate its growth potential.

LHI.US will need to effectively communicate its value proposition and growth strategy to potential investors. The company's strong focus on research and development, coupled with its commitment to quality and innovation, will be key factors in attracting investment. The company's leadership in the homeopathic products market, with a 41% share in the China Hong Kong market, further strengthens its position.